基于T细胞的癌症免疫疗法中人工抗原呈递细胞的基础

Neal Lillian R, Bailey Stefanie R, Wyatt Megan M, Bowers Jacob S, Majchrzak Kinga, Nelson Michelle H, Haupt Carl, Paulos Chrystal M, Varela Juan C

Department of Microbiology & Immunology, Medical University of South Carolina, Charleston, SC 29425.

Department of Dermatological Surgery and Dermatology, Medical University of South Carolina, Charleston, SC 29425.

J Immunol Res Ther. 2017;2(1):68-79. Epub 2017 Jun 26.

Adoptive T cell transfer (ACT) can mediate objective responses in patients with advanced malignancies. There have been major advances in this field, including the optimization of the generation of tumor-reactive lymphocytes to ample numbers for effective ACT therapy via the use of natural and artificial antigen presenting cells (APCs). Herein we review the basic properties of APCs and how they have been manufactured through the years to augment vaccine and T cell-based cancer therapies. We then discuss how these novel APCs impact the function and memory properties of T cells. Finally, we propose new ways to synthesize aAPCs to augment the therapeutic effectiveness of antitumor T cells for ACT therapy.

过继性T细胞转移（ACT）可介导晚期恶性肿瘤患者产生客观反应。该领域已取得重大进展，包括通过使用天然和人工抗原呈递细胞（APC），将肿瘤反应性淋巴细胞扩增至足够数量以进行有效的ACT治疗。在此，我们综述了APC的基本特性，以及多年来它们是如何被制造出来以增强基于疫苗和T细胞的癌症治疗的。然后，我们讨论这些新型APC如何影响T细胞的功能和记忆特性。最后，我们提出合成人工APC的新方法，以增强抗肿瘤T细胞用于ACT治疗的疗效。